Browsing Tag
atypical hemolytic uremic syndrome
3 posts
Why complement pathway competition in renal disease is intensifying around oral C5aR therapies
InflaRx N.V. is expanding izicopan across renal diseases as complement therapy competition intensifies. Discover what this means for nephrology markets.
Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS
Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS…
Alexion Pharmaceuticals bags Ultomiris FDA approval for atypical HUS
Ultomiris FDA approval : Alexion Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for…